Kyverna Therapeutics is developing miv-cel, a potential first-in-class CAR T therapy for severe B-cell-driven autoimmune diseases. The company recently aligned with regulators to submit a rolling Biologics License Application (BLA) for stiff person syndrome (SPS), supported by promising Phase 2 data showing efficacy and safety. With $236 million in cash and a $150 million credit facility, Kyverna is financially positioned to complete trials and prepare for commercial launch, targeting FDA approval by late 2026. The broader potential of miv-cel in other autoimmune diseases like generalized myasthenia gravis (gMG) could offer significant upside if regulatory and commercial milestones are met.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Viasat and BMW Group have successfully demonstrated the first integrated automotive satellite voice call, allowing drivers to make calls directly through the car's infotainment system even in areas without cellular coverage. This advancement, utilizi...
Iran has warned it will retaliate fiercely if the US targets its infrastructure, following President Trump's threat to strike Iranian power plants and bridges next week if negotiations fail. The US recently conducted airstrikes against Iranian milita...
Solana (SOL) maintains its price in the mid-$70 range, supported by several key developments. These include Circle's recent issuance of $500 million in USDC on the Solana network, increasing liquidity and transactional demand. Additionally, instituti...
